search results for 
Logo

Fresenius SE & Co. KGaA
Consolidated segment reporting

by business segment


1 Including special items from the acquisition of APP Pharmaceuticals, Inc. (since 2012: Fresenius Kabi USA, Inc.) 2 Including special items from the acquisition of Liberty Dialysis Holdings, Inc., from the renegotiation of the Venofer contract and the donation to the American Society of Nephrology 3 Including one-time costs related to the takeover offer to the shareholders of RHÖN-KLINIKUM AG 4 Excluding special items from the acquisition of Liberty Dialysis Holdings, Inc., from the renegotiation of the Venofer contract and the donation to the American Society of Nephrology 5 Before one-time costs related to the takeover offer to the shareholders of RHÖN-KLINIKUM AG, special items from the renegotiation of the Venofer contract and the donation to the American Society of Nephrology 6 The underlying pro forma EBIT does not include one-time costs related to the takeover offer to the shareholders of RHÖN-KLINIKUM AG, special items from the renegotiation of the Venofer contract and the donation to the American Society of Nephrology.


The consolidated segment reporting by business segment is an integral part of the notes.
The following notes are an integral part of the consolidated financial statements.
  Fresenius Medical Care Fresenius Kabi Fresenius Helios Fresenius Vamed Corporate / Other Fresenius Group
€ in millions 20124 2011 Change 2012 2011 Change 2012 2011 Change 2012 2011 Change 20122, 3 20111 Change 2012 2011 Change
Sales 10,741 9,031 19% 4,539 3,964 15% 3,200 2,665 20% 846 737 15% -36 -36 0% 19,290 16,361 18%
thereof contribution to consolidated sales 10,724 9,016 19% 4,489 3,916 15% 3,200 2,665 20% 846 737 15% 31 27 15% 19,290 16,361 18%
thereof intercompany sales 17 15 13% 50 48 4% 0 0   - - -- -67 -63 -6% 0 0  
contribution to consolidated sales 56% 55%   23% 24%   17% 16%   4% 5%   0% 0%   100% 100%  
EBITDA 2,282 1,891 21% 1,101 955 15% 432 369 17% 59 51 16% -115 -29 -- 3,759 3,237 16%
Depreciation and amortization 469 400 17% 167 152 10% 110 99 11% 8 7 14% 22 16 38% 776 674 15%
EBIT 1,813 1,491 22% 934 803 16% 322 270 19% 51 44 16% -137 -45 -- 2,983 2,563 16%
Net interest -332 -213 -56% -286 -278 -3% -67 -51 -31% -1 2 -150% 20 9 122% -666 -531 -25%
Income taxes -502 -432 -16% -166 -145 -14% -42 -43 2% -14 -11 -27% 65 27 141% -659 -604 -9%
Net income attributable to shareholders of Fresenius SE & Co. KGaA 870 770 13% 444 354 25% 203 163 25% 35 34 3% -626 -631 1% 926 690 34%
                                     
Operating cash flow 1,587 1,039 53% 596 462 29% 240 294 -18% 35 -83 142% -20 -23 13% 2,438 1,689 44%
Cash flow before acquisitions and dividends 1,069 629 70% 357 289 24% 69 138 -50% 24 -89 127% -33 -36 8% 1,486 931 60%
                                     
Total assets 16,921 15,096 12% 8,662 7,282 19% 4,408 3,495 26% 676 594 14% -3 -146 98% 30,664 26,321 17%
Debt 6,290 5,573 13% 4,964 4,395 13% 1,293 1,104 17% 74 44 68% -1,593 -1,317 -21% 11,028 9,799 13%
Capital expenditure, gross 526 429 23% 276 177 56% 180 157 15% 11 7 57% 14 13 8% 1,007 783 29%
Acquisitions, gross / investments 1,408 1,429 -1% 877 11 -- 579 45 -- 44 3 -- 264 124 113% 3,172 1,612 97%
                                     
Research and development expenses 87 80 9% 194 162 20% - - -- 0 0   24 25 -4% 305 267 14%
Employees (per capita on balance sheet date) 90,866 83,476 9% 30,214 24,106 25% 42,881 37,198 15% 4,432 3,724 19% 931 847 10% 169,324 149,351 13%
                                     
Key figures                                    
EBITDA margin 21.2% 20.9%   24.3% 24.1%   13.5% 13.8%   7.0% 6.9%         20.0%5 19.8%  
EBIT margin 16.9% 16.5%   20.6% 20.3%   10.1% 10.1%   6.0% 6.0%         15.9%5 15.7%  
Depreciation and amortization in % of sales 4.4% 4.4%   3.7% 3.8%   3.4% 3.7%   0.9% 0.9%         4.0% 4.1%  
Operating cash flow in % of sales 14.8% 11.5%   13.1% 11.7%   7.5% 11.0%   4.1% -11.3%         12.6% 10.3%  
ROOA 11.4% 12.0%   12.3% 12.4%   8.2% 8.4%   12.8% 16.0%         11.0%6 10.9%  

1 Including special items from the acquisition of APP Pharmaceuticals, Inc. (since 2012: Fresenius Kabi USA, Inc.) 2 Including special items from the acquisition of Liberty Dialysis Holdings, Inc., from the renegotiation of the Venofer contract and the donation to the American Society of Nephrology 3 Including one-time costs related to the takeover offer to the shareholders of RHÖN-KLINIKUM AG 4 Excluding special items from the acquisition of Liberty Dialysis Holdings, Inc., from the renegotiation of the Venofer contract and the donation to the American Society of Nephrology 5 Before one-time costs related to the takeover offer to the shareholders of RHÖN-KLINIKUM AG, special items from the renegotiation of the Venofer contract and the donation to the American Society of Nephrology 6 The underlying pro forma EBIT does not include one-time costs related to the takeover offer to the shareholders of RHÖN-KLINIKUM AG, special items from the renegotiation of the Venofer contract and the donation to the American Society of Nephrology.


The consolidated segment reporting by business segment is an integral part of the notes.
The following notes are an integral part of the consolidated financial statements.
  Fresenius Medical Care Fresenius Kabi Fresenius Helios Fresenius Vamed Corporate / Other Fresenius Group
€ in millions 20124 2011 Change 2012 2011 Change 2012 2011 Change 2012 2011 Change 20122, 3 20111 Change 2012 2011 Change
Sales 10,741 9,031 19% 4,539 3,964 15% 3,200 2,665 20% 846 737 15% -36 -36 0% 19,290 16,361 18%
thereof contribution to consolidated sales 10,724 9,016 19% 4,489 3,916 15% 3,200 2,665 20% 846 737 15% 31 27 15% 19,290 16,361 18%
thereof intercompany sales 17 15 13% 50 48 4% 0 0   - - -- -67 -63 -6% 0 0  
contribution to consolidated sales 56% 55%   23% 24%   17% 16%   4% 5%   0% 0%   100% 100%  
EBITDA 2,282 1,891 21% 1,101 955 15% 432 369 17% 59 51 16% -115 -29 -- 3,759 3,237 16%
Depreciation and amortization 469 400 17% 167 152 10% 110 99 11% 8 7 14% 22 16 38% 776 674 15%
EBIT 1,813 1,491 22% 934 803 16% 322 270 19% 51 44 16% -137 -45 -- 2,983 2,563 16%
Net interest -332 -213 -56% -286 -278 -3% -67 -51 -31% -1 2 -150% 20 9 122% -666 -531 -25%
Income taxes -502 -432 -16% -166 -145 -14% -42 -43 2% -14 -11 -27% 65 27 141% -659 -604 -9%
Net income attributable to shareholders of Fresenius SE & Co. KGaA 870 770 13% 444 354 25% 203 163 25% 35 34 3% -626 -631 1% 926 690 34%
                                     
Operating cash flow 1,587 1,039 53% 596 462 29% 240 294 -18% 35 -83 142% -20 -23 13% 2,438 1,689 44%
Cash flow before acquisitions and dividends 1,069 629 70% 357 289 24% 69 138 -50% 24 -89 127% -33 -36 8% 1,486 931 60%
                                     
Total assets 16,921 15,096 12% 8,662 7,282 19% 4,408 3,495 26% 676 594 14% -3 -146 98% 30,664 26,321 17%
Debt 6,290 5,573 13% 4,964 4,395 13% 1,293 1,104 17% 74 44 68% -1,593 -1,317 -21% 11,028 9,799 13%
Capital expenditure, gross 526 429 23% 276 177 56% 180 157 15% 11 7 57% 14 13 8% 1,007 783 29%
Acquisitions, gross / investments 1,408 1,429 -1% 877 11 -- 579 45 -- 44 3 -- 264 124 113% 3,172 1,612 97%
                                     
Research and development expenses 87 80 9% 194 162 20% - - -- 0 0   24 25 -4% 305 267 14%
Employees (per capita on balance sheet date) 90,866 83,476 9% 30,214 24,106 25% 42,881 37,198 15% 4,432 3,724 19% 931 847 10% 169,324 149,351 13%
                                     
Key figures                                    
EBITDA margin 21.2% 20.9%   24.3% 24.1%   13.5% 13.8%   7.0% 6.9%         20.0%5 19.8%  
EBIT margin 16.9% 16.5%   20.6% 20.3%   10.1% 10.1%   6.0% 6.0%         15.9%5 15.7%  
Depreciation and amortization in % of sales 4.4% 4.4%   3.7% 3.8%   3.4% 3.7%   0.9% 0.9%         4.0% 4.1%  
Operating cash flow in % of sales 14.8% 11.5%   13.1% 11.7%   7.5% 11.0%   4.1% -11.3%         12.6% 10.3%  
ROOA 11.4% 12.0%   12.3% 12.4%   8.2% 8.4%   12.8% 16.0%         11.0%6 10.9%  

by region


  Europe North America Asia-Pacific Latin America Africa Fresenius Group
€ in millions 2012 2011 Change 2012 2011 Change 2012 2011 Change 2012 2011 Change 2012 2011 Change 2012 2011 Change
The consolidated segment reporting by region is an integral part of the notes.
The following notes are an integral part of the consolidated financial statements.
Sales 7,797 6,919 13% 8,144 6,601 23% 1,899 1,582 20% 1,126 899 25% 324 360 -10% 19,290 16,361 18%
contribution to consolidated sales 40% 42%   42% 40%   10% 10%   6% 6%   2% 2%   100% 100%  
EBIT 746 758 -2% 1,700 1,382 23% 321 251 28% 158 125 26% 58 47 23% 2,983 2,563 16%
Depreciation and amortization 357 322 11% 328 268 22% 52 50 4% 33 29 14% 6 5 20% 776 674 15%
                                     
Total assets 11,089 9,759 14% 16,424 13,670 20% 2,085 1,888 10% 929 877 6% 137 127 8% 30,664 26,321 17%
Capital expenditure, gross 532 422 26% 326 210 55% 83 69 20% 59 71 -17% 7 11 -36% 1,007 783 29%
Acquisitions, gross / investments 914 924 -1% 2,238 596 -- 11 75 -85% 9 17 -47% - - -- 3,172 1,612 97%
                                     
Employees (per capita on balance sheet date) 81,777 74,415 10% 58,264 47,701 22% 14,315 13,134 9% 13,485 12,754 6% 1,483 1,347 10% 169,324 149,351 13%

  Europe North America Asia-Pacific Latin America Africa Fresenius Group
€ in millions 2012 2011 Change 2012 2011 Change 2012 2011 Change 2012 2011 Change 2012 2011 Change 2012 2011 Change
The consolidated segment reporting by region is an integral part of the notes.
The following notes are an integral part of the consolidated financial statements.
Sales 7,797 6,919 13% 8,144 6,601 23% 1,899 1,582 20% 1,126 899 25% 324 360 -10% 19,290 16,361 18%
contribution to consolidated sales 40% 42%   42% 40%   10% 10%   6% 6%   2% 2%   100% 100%  
EBIT 746 758 -2% 1,700 1,382 23% 321 251 28% 158 125 26% 58 47 23% 2,983 2,563 16%
Depreciation and amortization 357 322 11% 328 268 22% 52 50 4% 33 29 14% 6 5 20% 776 674 15%
                                     
Total assets 11,089 9,759 14% 16,424 13,670 20% 2,085 1,888 10% 929 877 6% 137 127 8% 30,664 26,321 17%
Capital expenditure, gross 532 422 26% 326 210 55% 83 69 20% 59 71 -17% 7 11 -36% 1,007 783 29%
Acquisitions, gross / investments 914 924 -1% 2,238 596 -- 11 75 -85% 9 17 -47% - - -- 3,172 1,612 97%
                                     
Employees (per capita on balance sheet date) 81,777 74,415 10% 58,264 47,701 22% 14,315 13,134 9% 13,485 12,754 6% 1,483 1,347 10% 169,324 149,351 13%

Continue reading:
Notes